Adeza Biomedical Announces Appointment of Vice President of Medical Affairs.

SUNNYVALE, Calif.--(BW HealthWire)--Nov. 4, 1998--

Durlin E. Hickok, M.D., M.P.H. Joins Adeza Biomedical 

in Key Clinical Management Position

Adeza Biomedical Corporation has appointed Durlin E. Hickok, M.D., M.P.H. as Vice President of Medical Affairs.

In this key position, Dr. Hickok will be working with all facets of clinical management. His primary function will be to oversee clinical and regulatory affairs, establish care pathways/guidelines, identify new research projects, interact with physicians, and work closely with managed care organizations.

Dr. Hickok continues to hold an academic appointment at the University of Washington as Clinical Professor of Epidemiology and Ob/Gyn in addition to being a member of the Graduate Faculty. He has more than 80 publications on topics including preterm delivery, preeclampsia and other aspects of pregnancy care and testing.

Prior to joining Adeza, Dr. Hickok was Vice President and Medical Director for Omnia, Inc., a health care company that develops and manages regional Ob/Gyn networks. Dr. Hickok's residency and fellowship training were at the University of Washington, Department of Ob/Gyn, where he also received a Masters Degree in Public Health through the Robert Wood Johnson Clinical Scholars Program. He has served in a variety of capacities including Chief of the Department of Ob/Gyn at Virginia Mason Medical Center in Seattle, Washington.

Emory V. Anderson, president stated, "We're delighted about Dr. Hickok joining Adeza in this key clinical management position. His addition to our team will enable us to further reinforce Adeza's commitment to women's health care -- providing the care path to healthier outcomes."

Adeza Biomedical is located in Sunnyvale, California, in the heart of Silicon Valley. Adeza designs, develops, manufactures and markets diagnostic products and services targeted to women's health care, focusing primarily on the diagnosis of pregnancy-related and female reproductive disorders, including preterm birth, preeclampsia, endometriosis and infertility. In September 1998, Adeza received FDA approval for its TLi(TM) System for rapid Fetal Fibronectin testing, which marks a significant breakthrough for the assessment of a pregnant woman's likelihood of delivering prematurely. Adeza's website is located at www.adeza.com.